PTCT · Ptc Therapeutics, Inc.
$69.30
-2.10 (-2.94%)
At close · Sep 4
View the 10-K filed Feb 19, 2026
Customer concentration
— top 4 customers 10% of revenue
4 customers — 10% of revenue (2025)
“During 2025, four of our distributors each accounted for over 10% of our net product sales.”
Market Cap
$5.96B
Shares
83.46M
Income-statement, balance-sheet and cash-flow figures from SEC filings, plus a debt profile anchored in the latest 10-K and updated by each 10-Q and debt exhibit.
Revenue
$1.73B
+114.5%
FY2025
Net Income
$682.64M
+287.9%
FY2025
Gross Margin
96.05%
+0.8pp
FY2019
Operating Margin
50.09%
+87.6pp
FY2025
Diluted EPS
$7.78
+264.5%
FY2025
Operating Cash Flow
$711.2M
+760.4%
FY2025
Chart any reported metric, KPI or segment over time — the full statement history lives here
Search above to add metrics — fundamentals, product and segment revenue, company KPIs, valuation.
| Line Item | TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | FY2015 | FY2014 | FY2013 | FY2012 | FY2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| $1.01B | $1.73B | $806.78M | $937.82M | $698.8MG | $538.59M | $380.77M | $306.98M | $264.73M | $194.39M | $82.71M | $36.77M | $25.25M | $34.7M | $33.95M | $105.41M | |
| — | — | — | — | — | — | — | $12.14M | $12.67M | $4.58M | $0 | $0 | — | — | — | — | |
| — | — | — | — | — | — | — | $294.85M | $252.06M | $189.82M | $82.71M | $36.77M | — | — | — | — | |
| — | — | — | — | — | — | — | 96.05% | 95.21% | 97.65% | 100% | 100% | — | — | — | — | |
| $433.31M | $455.25M | $534.48M | $666.56M | $651.5M | $540.68M | $477.64M | $257.45M | $171.98M | $117.46M | $117.63M | $121.82M | $79.84M | $54.88M | $46.14M | $58.68M | |
| — | — | — | — | — | — | — | — | — | $121.27M | $97.13M | $82.08M | $44.82M | $25.22M | $14.62M | $16.15M | |
| $347.73M | $347.14M | $300.91M | $332.54M | $326M | $285.77M | $245.16M | $202.54M | $153.55M | $121.27M | $97.13M | — | — | — | — | — | |
| $40.31M | $24.74M | $60.74M | $222.64M | $116.55M | $54.75M | $36.89M | $27.65M | $22.88M | $15.38M | $0 | $0 | — | — | — | — | |
| $55.3M | $38.82M | $75.66M | $236.59M | $128.84M | $64.13M | $43.49M | $32.18M | $26.09M | $17.68M | $3.29M | $2.88M | — | — | — | — | |
| — | — | — | — | — | — | — | — | — | $0 | — | — | — | — | — | — | |
| $883.15M | $863.72M | $1.11B | $1.38B | $1.15B | $913.04M | $812.53M | $548.14M | $380.42M | $258.68M | $214.76M | $203.9M | $124.66M | $80.09M | $60.75M | $74.83M | |
| $125.6M | $866.94M | -$302.57M | -$439.5M | -$447.41M | -$374.44M | -$431.77M | -$241.16M | -$115.69M | -$64.29M | -$132.06M | -$167.13M | -$99.41M | -$45.4M | -$26.81M | $30.58M | |
| — | 50.09% | -37.5% | -46.86% | -64.03% | -69.52% | -113.39% | -78.56% | -43.7% | -33.07% | -159.67% | -454.58% | -393.79% | -130.85% | -78.97% | 29.01% | |
| $180.9M | $905.75M | -$226.91M | -$202.91M | -$318.57M | -$310.31M | -$388.28M | -$208.98M | -$89.6M | -$46.61M | -$128.77M | -$164.25M | — | — | — | — | |
| -$7.39M | -$18.09M | $6.54M | $10.13M | -$49.21M | -$57.88M | $85.19M | $13.72M | $129K | -$1.28M | -$1.21M | -$465K | -$213K | $38K | $1.78M | $461.36K | |
| -$67.07M | $696.62M | -$363.12M | -$696.11M | -$587.49M | -$518.34M | -$402.93M | -$239.93M | -$128.11M | -$77.67M | -$141.54M | -$169.96M | -$98.45M | -$51.57M | -$26.24M | $28.6M | |
| -$28.69M | $13.98M | $176K | -$69.51M | -$28.47M | $5.56M | $35.23M | $11.65M | -$29K | $1.34M | $569K | $485K | -$4.69M | — | — | -$2.31M | |
| -$38.38M | $682.64M | -$363.3M | -$626.6M | -$559.02M | -$523.9M | -$438.16M | -$251.58M | -$128.08M | -$79M | -$142.11M | -$170.45M | -$93.75M | -$51.57M | -$26.24M | $30.9M | |
| — | 39.44% | -45.03% | -66.81% | -80% | -97.27% | -115.07% | -81.95% | -48.38% | -40.64% | -171.83% | -463.6% | -371.37% | -148.65% | -77.28% | 29.32% | |
| -$38.38M | $682.64M | -$363.3M | -$626.6M | -$559.02M | -$523.9M | -$438.16M | -$251.58M | -$128.08M | — | — | -$170.45M | -$93.75M | -$66.43M | $731K | $26.07K | |
| -$39.72M | $719.03M | -$387.9M | -$632.69M | -$529.94M | -$487.23M | -$488.53M | -$263.62M | -$130.59M | -$73.55M | -$142.4M | -$170.91M | -$94.56M | -$51.5M | -$26.24M | $30.9M | |
| USD/shares | -$0.70 | $8.58 | -$4.73 | -$8.37 | -$7.79 | -$7.43 | -$6.64 | -$4.27 | -$2.75 | -$2.02 | — | — | -$2.97 | -$5.18 | $219.76 | $23.95 |
| USD/shares | -$0.54 | $7.78 | -$4.73 | -$8.37 | -$7.79 | -$7.43 | -$6.64 | -$4.27 | — | — | — | — | -$2.97 | -$5.18 | $42.50 | $4.55 |
| shares | — | 79.53M | 76.85M | 74.84M | 71.73M | 70.47M | 66.03M | 58.86M | 46.58M | 39.18M | 34.04M | 33.63M | 31.57M | 12.83M | 3328 | 1089 |
| shares | — | 88.31M | 76.85M | 74.84M | 71.73M | 70.47M | 66.03M | 58.86M | 46.58M | 39.18M | 34.04M | 33.63M | 31.57M | 12.83M | 17.21K | 5729 |
Italic rows are computed from reported lines — open a row's info icon for its formula. Values reflect the latest filing (restatements included); per-share figures on today's split basis. Click a value for its source filing.
TTM: trailing twelve months through the latest reported quarter — flows sum the last four quarters, balances take the latest. 3Y/5Y/10Y columns are trailing CAGR from the newest fiscal year; blank where an endpoint is missing or negative. (G): the company's own guidance — a (G) column is a guided period not yet reported; a G marker shows how the reported figure landed against the guided range. Non-GAAP-basis guidance (*) is shown as stated and never judged against GAAP actuals.
Debt Profile
Annual debt figures are established from 10-K filings and updated by subsequent 10-Q and 8-K disclosures. Instrument balances are not summed into a company total unless the filing itself reports that total.
Coverage backlog: 56 eligible filings and 0 covenant artifacts have no current-version terminal extraction result. This includes untouched sources and sources on the retry ladder.
No terminal debt extraction result is available yet; this is not evidence that the company has no debt.
Price & Valuation
Multiples computed on the strict TTM/EV methodology — today's snapshot against peers, and each ratio recomputed as of past filing dates.
Valuation
EV/Revenue
—
Peer median 8.64×
EV/EBIT
—
Peer median 26.88×
P/E (TTM)
—
Peer median 19.68×
Peer medians compare against the 182 similar-size Biotechnology companies (of 515 listed).
Valuation over time computed as of each quarter's filing date
Revenue Breakdown
Annual revenue as the company disaggregates it in its own XBRL filings. Years a component wasn't reported show a dash.
Share mode is each component's slice of the reported components that year — issuers rarely tag every revenue dollar, so slices need not sum to total revenue.
By Segment (USD)
| Component | FY2025 | FY2024 | FY2023 | FY2022 |
|---|---|---|---|---|
| Life Science Segment | $1,730,655,000 | $806,780,000 | $937,822,000 | $698,801,000 |
By Geography (USD)
| Component | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| United States | $252,185,000 | $207,215,000 | $255,087,000 | $381,862,000 | $297,005,000 | $186,396,000 | $116,676,000 | $93,694,000 |
| Non Us | $235,888,000 | $393,736,000 | $406,161,000 | $316,939,000 | $241,588,000 | $194,370,000 | $190,304,000 | $171,040,000 |
| All Other Countries Other Than Russia Brazil And United States | $168,412,000 | $197,472,000 | $238,510,000 | — | — | — | — | — |
| Russia | $100,445,000 | $105,377,000 | $85,974,000 | — | — | — | — | — |
| Brazil | $65,661,000 | $72,081,000 | $58,606,000 | — | — | — | — | — |
By Product & Service (USD)
| Component | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Collaboration and License Revenue | $998,357,000 | $304,000 | $100,030,000 | — | — | — | — | — |
| Product | $586,703,000 | $582,145,000 | $638,177,000 | $535,228,000 | $428,904,000 | $333,401,000 | $291,306,000 | $263,005,000 |
| Royalty | $244,224,000 | $203,864,000 | $168,856,000 | $113,521,000 | $54,643,000 | $4,786,000 | — | — |
| Translarna1 | $235,299,000 | $321,071,000 | $332,753,000 | — | — | — | — | — |
| Emflaza | $146,361,000 | $207,215,000 | $255,087,000 | — | — | — | — | — |
| Sephience | $111,153,000 | — | — | — | — | — | — | — |
| Upstaza and Kebilidi | $56,626,000 | $16,913,000 | $18,841,000 | — | — | — | — | — |
| Other Products | $37,264,000 | $36,946,000 | $31,496,000 | — | — | — | — | — |
| Translarna | -$98,629,000 | $18,806,000 | $23,072,000 | — | — | — | — | — |
| Collaboration Revenue | — | $304,000 | $100,030,000 | $50,052,000 | $55,046,000 | — | — | — |
| Grant And Collaboration | — | — | — | — | — | $42,579,000 | $15,674,000 | $1,729,000 |
| Manufacturing | — | $1,661,000 | $7,687,000 | — | — | — | — | — |
Key facts
CIK
1070081
CUSIP
69366J200
13F (30d)
271 filings
263 filers
Visit website
Investor relations